Review
Open access
Oct 2026
Empagliflozin’s role in cardiometabolic disease treatment: an Egyptian expert’s view
Given the expanding therapeutic indications of empagliflozin (EMPA) beyond glycemic control and the growing burden of cardiometabolic diseases, this review evaluated its efficacy, safety, and cost-effectiveness in the Egyptian population within the global context. A comprehensive literature review of PubMed and Google...
S. H. Assaad-Khalil, Fawzy Elmessallamy, K. E. Elhadidy et al.
· Diabetology & Metabolic Synd... · 0 citations